Healthcare • NASDAQ
According to Zyberno, CRONOS GROUP INC. (CRON) is not a buy — AVERAGE BUSINESS (62/100) with a negative Margin of Safety of -47.7% and a Brina Gap of -11.8% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, CRONOS GROUP INC. (CRON) trades at $3.38 against an estimated intrinsic value per share of $2.29 — a -47.7% Margin of Safety based on Owner Earnings of $27.48M TTM, projected at 29.5% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -11.8% weakens the case: based on the company's ROIC (3.9%) and reinvestment rate (44.4%), the business can fundamentally grow at 1.7% — but the current enterprise value implies the market expects 13.5%. This places CRON in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 11.0% annually.
Over the trailing twelve months, CRON generated $27.48M in Owner Earnings. Capital was deployed as follows: $16.73M returned via share buybacks, $6.41M paid as dividends, $12.33M invested in capital expenditures. Reinvestment rate: 44.4%. Owner Earnings have grown at 29.5% annually over the trailing five years using log-linear regression.